Monte Rosa Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Monte Rosa Therapeutics, Inc | ||
| Date: March 17, 2026 | By: | /s/ Markus Warmuth |
|---|---|---|
| Markus Warmuth | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Markus Warmuth | President, Chief Executive Officer and Director | March 17, 2026 |
| Markus Warmuth, M.D. | (Principal Executive Officer and Principal Financial Officer) | |
| /s/ Edmund Dunn | SVP, Corporate Controller | March 17, 2026 |
| Edmund Dunn, CPA | (Principal Accounting Officer) | |
| /s/ Ali Behbahani | Director | March 17, 2026 |
| Ali Behbahani | ||
| /s/ Kimberly L. Blackwell | Director | March 17, 2026 |
| Kimberly L. Blackwell | ||
| /s/ Andrew Schiff | Director | March 17, 2026 |
| Andrew Schiff | ||
| /s/ Chandra P. Leo | Director | March 17, 2026 |
| Chandra P. Leo | ||
| /s/ Christine Siu | Director | March 17, 2026 |
| Christine Siu | ||
| /s/ Jan Skvarka | Director | March 17, 2026 |
| Jan Skvarka | ||
| /s/ Anthony Manning | Director | March 17, 2026 |
| Anthony Manning | ||
| /s/ Eric A. Hughes | Director | March 17, 2026 |
| Eric A. Hughes | ||
Index to consolidated financial statements
| Page | |
| Report of independent registered public accounting firm (PCAOB ID No. 34) | F-2 |
|---|---|
| Audited consolidated financial statements | |
| Consolidated balance sheets | F-3 |
| - | |
| Consolidated statements of operations and comprehensive loss | F-4 |
| Consolidated statements of stockholders’ equity | F-5 |
| Consolidated statements of cash flows | F-6 |
| Notes to the consolidated financial statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.